Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Entrada Therapeutics (TRDA) Equity Ratio (2022 - 2025)

Entrada Therapeutics has reported Equity Ratio over the past 4 years, most recently at 0.81 for Q4 2025.

  • Quarterly results put Equity Ratio at 0.81 for Q4 2025, changed 0.4% from a year ago — trailing twelve months through Dec 2025 was 0.81 (changed 0.4% YoY), and the annual figure for FY2025 was 0.81, changed 0.4%.
  • Equity Ratio for Q4 2025 was 0.81 at Entrada Therapeutics, down from 0.83 in the prior quarter.
  • Over the last five years, Equity Ratio for TRDA hit a ceiling of 0.88 in Q1 2022 and a floor of 0.42 in Q2 2023.
  • Median Equity Ratio over the past 4 years was 0.81 (2024), compared with a mean of 0.72.
  • Biggest five-year swings in Equity Ratio: plummeted 51.59% in 2023 and later surged 76.37% in 2024.
  • Entrada Therapeutics' Equity Ratio stood at 0.84 in 2022, then tumbled by 38.75% to 0.52 in 2023, then skyrocketed by 57.68% to 0.81 in 2024, then decreased by 0.4% to 0.81 in 2025.
  • The last three reported values for Equity Ratio were 0.81 (Q4 2025), 0.83 (Q3 2025), and 0.85 (Q2 2025) per Business Quant data.